Ranbaxy extends branded Diovan's life

Share this article:

Four Ranbaxy sites are on the FDA's list of black sites, and while this may seem like bad news for the Sun Pharma subsidiary, the division's manufacturing slip-ups have been to Novartis's benefit: Bloomberg reports that because of the way generic licenses are granted, license-holder Ranbaxy's paralysis has kept generic Diovan off the market, which means Novartis's branded Diovan remains king of the pharmacy.

As Bloomberg explains, the law is that the generics license is Ranbaxy's and competitors can't join the blood pressure medication fray until its generic has had six months in the market. Only thing is, the FDA has not approved the generic, which puts Ranbaxy's generic and therefore other manufacturer generics in limbo.

By Bloomberg's count, this delay translates into around $900 million in lost consumer savings.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.